16:27 EST UroGen Pharma (URGN) files automatic mixed securities shelf
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on URGN:
- Urogen Pharma’s Promising Growth and Demand Surge Support Buy Rating
- UroGen Pharma reports Q3 EPS (69c), consensus (68c)
- UroGen Pharma announces preliminary results from Phase 3 UTOPIA trial
- UroGen Pharma’s UGN-104 Study: A Potential Game-Changer in Urothelial Cancer Treatment
- UroGen Pharma’s Phase 3 Study on UGN-103: A Potential Game-Changer in Bladder Cancer Treatment